Fig. 1

Cumulative incidence of all-grade hyperglycemic events among patients in SOLAR-1 treated with alpelisib + fulvestrant (A) or grade 3/4 hyperglycemic events among patients in SOLAR-1 treated with alpelisib + fulvestrant (B). Time to first medication vs first hyperglycemic event in patients treated with alpelisib from SOLAR-1 who had a hyperglycemia adverse event and was treated by antihyperglycemic medication (C) and subsequent grade of hyperglycemia among patients in SOLAR-1 with early (first quantile of time from hyperglycemia to treatment) and late (fourth quantile) treatment with antihyperglycemic medication (D). Cumulative incidence curves using Kaplan–Meier method. Hyperglycemic events by Standardized MedDRA query. AE, adverse event; G, grade